Molecular targeted enhanced ultrasound imaging of flkl reveals diagnosis and prognosis potential in a genetically engineered mouse prostate cancer model

Molecular Imaging

Volumn 8, Issue 4, 2009, Pages 209-220

  Xuan, Jim W ^a   Bygrave, Michael ^b   Valiyeva, Fatma ^b   Moussa, Madeleine ^b   Izawa, Jonathan I ^b   Bauman, Glenn S ^b   Klibanov, Alexander ^b   Wang, Fen ^b   Greenberg, Norman M ^b   Fenster, Aaron ^b  

^a LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; B-MODE IMAGING; BOUNDARY ZONES; CORRELATION STUDIES; HISTOCHEMICAL ANALYSIS; IMAGING TOOLS; LARGE SIZES; MICRO-BUBBLE; MICRO-IMAGING; MOLECULAR DIAGNOSTICS; MOLECULAR IMAGING; MOLECULAR SIGNALS; MOUSE MODELS; PELVIC NODES; PROSTATE CANCERS; SMALL TUMORS; SWITCH-ON; TARGETED IMAGING; TECHNIQUES USED; TUMOR CELLS; TUMOR GROWTH; TUMOR METASTASIS; TUMOR SIZE; ULTRASOUND IMAGING; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR;

ACOUSTIC WAVES; BLOOD VESSELS; DIAGNOSIS; DISEASES; ENDOTHELIAL CELLS; GENETIC ENGINEERING; HISTOLOGY; IMAGING TECHNIQUES; ONCOLOGY; PATHOLOGY; TUMORS; ULTRASONIC APPLICATIONS; ULTRASONICS;

ULTRASONIC IMAGING;

CONTRAST MEDIUM; DIAGNOSTIC AGENT; TUMOR MARKER; VASCULOTROPIN RECEPTOR 2;

ANIMAL; ARTICLE; C57BL MOUSE; CANCER DIAGNOSIS; CBA MOUSE; DRUG DELIVERY SYSTEM; ECHOGRAPHY; EVALUATION; IMAGE PROCESSING; MALE; METABOLISM; METASTASIS; METHODOLOGY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; THREE DIMENSIONAL IMAGING; TRANSGENIC MOUSE; VASCULARIZATION;

ANIMALS; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; EARLY DETECTION OF CANCER; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 70349319834     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2009.00020     Document Type: Article

References (29)

1. KlibanovAL. Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest Radiol 2006;41:354-362
2. Newman CMH, Bettinger T. Gene therapy progress and prospects: ultrasound for gene transfer. Gene Ther 2007;14:465-475
3. Kiessling F, Huppert J, Palmowski M. Functional and molecular ultrasound imaging: concepts and contrast agents. Curr Med Chem 2009;16:627-642
4. Schlaeppi JM, Wood JM. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev 1999;18:473-481
5. Yamashita J, Itoh H, Hirashima M, et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 2000; 408: 92-96 .
6. Heidenreich R, Kappel A, Breier G. Tumor endothelium- specific transgene expression directed by vascular endothelial growth factor receptor-2 (Flk1) promoter/enhancer sequences. Cancer Res 2000;60:6142-6147
7. Reynolds AR, Reynolds LE, Nagel TE, et al. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res 2004; 64: 8643-8650 .
8. Lee TH, Seng S, Sekine M, et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 2007; 4: e186 .
9. Abate-Shen C, Shen MM. Mouse models of prostate carcinogenesis. Trends Genet 2002; 18:S1-5.
10. Huss WJ, Maddison LA, Greenberg NM. Autochthonous mouse models for prostate cancer: past, present and future. Semin Cancer Biol 2001;11:245-260
11. Gabril MY, Onita T, Ji PG, et al. Prostate targeting:PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Ther 2002;9:1589-1599
12. Wirtzfeld LA, Wu GJ, Bygrave M, et al. Three-dimensional ultrasound micro-imaging for preclinical studies using a transgenic prostate cancer mouse model. Cancer Res 2005; 65: 6337-6345 .
13. Van Huizen I, Wu GJ, Moussa M, et al. Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models. Clin Cancer Res 2005;11:7911-7919
14. Xuan JW, Bygrave M, Jiang HY, et al. Functional neo-angio- genesis imaging of genetically engineered mouse prostate cancer using three-dimensional power Doppler ultrasound. Cancer Res 2007; 67: 2830-2839 .
15. Greenberg NM, Demayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995; 92: 3439-3443 .
16. Korpanty G, Carbon JG, Grayburn PA, et al. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 2007; 13: 323-330 .
17. Haag P, Frauscher F, Gradl J, et al. Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours. J Steroid Biochem Mol Biol 2006;102:103-113
18. Weller GE, Wong MK, Modzelewski RA, et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine- leucine. Cancer Res 2005;65:533-539
19. Duan WM, Gabril MY, Moussa M, et al. Knock-in of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate (KIMAP) model demonstrates advantageous features over the transgenic model. Oncogene 2005;24:1510-1524
20. Gabril MY, Duan WM, Wu GJ, et al. A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies. Mol Ther 2005;11:348-362
21. Cook MJ. The anatomy of the laboratory mouse. London: Academic Press; 1965.
22. Leong-Poi H, Christiansen J, Heppner P, et al. Assessment of endogenous and therapeutic arteriogenesis by contrast ultrasound molecular imaging of integrin expression. Circulation 2005;111:3248-3254
23. Fenster A, Downey DB, Cardinal HN. Three-dimensional ultrasound imaging. Phys Med Biol 2001;46:R67-99.
24. Shappell SB, Thomas GV, Roberts RL, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-2305
25. Huss WJ, Hanrahan CF, Barrios RJ, et al. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001;61:2736-2743
26. Christiansen JP, French BA, Klibanov AL, et al. Targeted tissue transfection with ultrasound destruction of plasmid-bearing cationic microbubbles. Ultrasound Med Biol 2003;29:1759-1767
27. Hou CC, Wang W, Huang XR, et al. Ultrasound-microbubble- mediated gene transfer of inducible Smad7 blocks transforming growth factor-signaling and fibrosis in rat remnant kidney. Am J Pathol 2005;166:761-771
28. Duvshani-Eshet M, Baruch L, Kesselman E, et al. Therapeutic ultrasound-mediated DNA to cell and nucleus: bioeffects revealed by confocal and atomic force microscopy. Gene Ther 2006;13:163-172
29. Chen S, Ding JH, Bekeredjian R, et al. Efficient gene delivery to pancreatic islets with ultrasonic microbubble destruction technology. Proc Natl Acad Sci U S A 2006;103:8469-8474